Immutep IMMP 深 滬
等待開盤 11-04 09:30:00 美东时间
2.995
-0.075
-2.44%
華盛通- 最 高3.12
- 今 開3.03
- 成交量 1.22万股
- 最 低 2.985
- 昨 收 3.07
- 總市值 2207.48万
- 52周最高 70.598
- 市盈率 靜 --
- 換手率 0.16%
- 52周最低 2.985
- 委 比 -46.99%
- 總股本 737.06万
- 歷史最高 159.00
- 量 比 0.77
- 振 幅 4.40%
- 歷史最低 2.985
- 每 手 1
- 風險率 21.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immutep Quarterly Activities Report Q1 FY27
Immutep focuses on advancing efti for HNSCC (CPS <1) and neoadjuvant STS, with trials targeting H2 CY27. IMP761, an anti-LAG-3 antibody for autoimmune diseases, is now a co-priority and will be featured at ACR 2026. The root cause analysis of TACTI-004 identified structural differences in efti manufacturing scales, leading to a new 200 L scale production. The company received A$0.86 million from Australia’s R&D Tax Incentive and €1.36 million fro...
10-29 12:00
Immutep Receives Cash Payment Of €1.36M From French Government Under Tax Incentive Program
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that it has received a cash payment of €1.36 million (approximately A$2.16 million) from the French Government under its Crédit d’Im...
10-28 20:02
Immutep Receives A$2.16 million French R&D Tax Incentive
Immutep Limited received a €1.36 million cash payment from the French Government under its CIR research tax incentive program for eligible R&D activities in 2025. This follows an A$0.86 million rebate from Australia and eligibility for Germany’s R&D tax incentive. The non-dilutive funding will support R&D for eftilagimod alfa (efti) and IMP761. Immutep’s cash reach extends into the first half of 2028.
10-28 12:00
IMMP收涨1.61%，成交额4.26万美元
10月28日，IMMP（IMMP）收涨1.61%，报3.15美元，成交额4.26万美元，市值2321.06万美元。 行情数据 • 开盘价：3.1美元 • 最高价...
10-28 07:44
Immutep Files 2026 Form 20-F, Confirms Accelerated Filer Status
Immutep Ltd ( ($AU:IMM) ) has shared an announcement. Immutep Limited has filed...
10-26 05:55
IMMP收跌0.94%，成交额2.16万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-20 07:50
Immutep's Abstract On IMP761 Accepted For Poster Presentation At ACR Convergence 2026
• Late-breaking poster will present data from the first-in-human Phase I study of IMP761, a first-in-class LAG-3 agonist antibody, in healthy volunteers
10-19 20:05
Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026
Immutep Limited will present late-breaking data from the Phase I study of IMP761, a first-in-class LAG-3 agonist antibody, at the ACR Convergence 2026. The study, conducted in healthy volunteers using CHDR’s KLH challenge model, aims to assess IMP761’s immunosuppressive effects. First interim results were presented at EULAR 2026. The poster, titled "IMP761, a Novel Immunosuppressive LAG-3 Agonist Antibody in the Clinic," will be available on Immu...
10-19 12:00
Immutep, Monash Win New ARC Grant to Advance LAG-3 Research
Immutep Ltd ( ($AU:IMM) ) has issued an announcement. Immutep Limited has secur...
10-14 06:32
Immutep Restores Nasdaq Bid Price Compliance with ADS Ratio Change
Immutep Ltd ( ($AU:IMM) ) has issued an update. Immutep Ltd has regained compli...
10-13 09:07
